TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07600749: A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants With Advanced/Metastatic Solid Tumors

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,005,768

Rescue Site Savings

+$4,618,152

Unlock Full NCT07600749 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07600749 Rescue Dossier →